STAAR Surgical Company (STAA)

Currency in USD
27.29
+0.10(+0.37%)
Closed·
27.02-0.27(-0.99%)
·
Earnings results expected tomorrow
STAA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
27.0528.19
52 wk Range
15.5930.81
Key Statistics
Prev. Close
27.19
Open
27.07
Day's Range
27.05-28.19
52 wk Range
15.59-30.81
Volume
732.17K
Average Volume (3m)
1.32M
1-Year Change
43.7829%
Book Value / Share
6.92
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
STAA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
21.11
Downside
-22.64%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

STAAR Surgical Company News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Analyst Ratings

2 Buy
9 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 21.11
(-22.64% Downside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Wedbush
Hold26.00-4.73%21.00Maintain09-04-2026
Stifel
Hold18.00-34.04%-Maintain09-04-2026
Needham
Hold---Maintain09-04-2026
Canaccord
Buy27.00-1.06%22.00Upgrade09-04-2026
Wells Fargo
Hold16.00-41.37%30.75Maintain05-03-2026

STAAR Surgical Company Earnings Call Summary for Q4/2025

  • STAAR Surgical Q4 2025 EPS of -$0.37 missed forecast of $0.15, triggering 2.05% stock decline to $18.66 in aftermarket trading.
  • Revenue rose 18% YoY to $57.8M driven by China recovery; gross margin improved to 75.7% from 64.7%, but adjusted EBITDA loss of $0.2M persisted.
  • Merger-related costs and restructuring expenses elevated operating costs, overshadowing revenue gains despite strong $187.5M cash position with no debt.
  • Company plans EVO+ launch in China and regulatory expansion while maintaining cost discipline to improve profitability amid operational challenges.
  • Analysts concerned about terminated Alcon merger impact and rising expenses; stock down 30.75% over six months with further sales decline anticipated.
Last Updated: 04-03-2026, 05:04 am
Read Full Transcript

Earnings

Latest Release
03-03-2026
EPS / Forecast
-0.37 / 0.15
Revenue / Forecast
239.4M / 75.37M
EPS Revisions
Last 90 days

STAA Income Statement

Compare STAA to Peers and Sector

Metrics to compare
STAA
Peers
Sector
Relationship
P/E Ratio
−16.8x−1.7x−0.5x
PEG Ratio
0.06−0.170.00
Price/Book
3.9x4.3x2.6x
Price / LTM Sales
5.6x2.3x3.3x
Upside (Analyst Target)
−19.1%49.7%47.1%
Fair Value Upside
Unlock9.3%6.2%Unlock

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists. The company sells its products directly through its sales representatives in Japan, the United States, Germany, Spain, Singapore, Canada, and the United Kingdom, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
15.17M30.63%412.42M
Other Institutional Investors
62.45M69.37%1.70B
Public Companies & Retail Investors
0.000.00%0.00
Total
77.62M100.00%2.11B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Broadwood Partners LP32.57%1,61,23,8424,38,407
Broadwood Capital, Inc.32.57%1,61,23,8424,38,407

FAQ

What Is the STAAR Surgical (STAA) Share Price Today?

The STAAR Surgical share price today is 27.29.

What is the current STAAR Surgical (STAA) share price and day range?

As of 05-05-2026, the STAAR Surgical share price is 27.29, with a previous close of 27.19. The share price has ranged from 27.05 to 28.19 today, while the 52-week range spans from 15.59 to 30.81.

What Is the STAAR Surgical Market Cap?

As of today, STAAR Surgical market cap is 1.35B.

What Is the STAAR Surgical (STAA) Share Price Target?

The average 12-month share price target for STAAR Surgical is 21.11, with a high estimate of 27 and a low estimate of 16. 2 analysts recommend buying, while 0 suggest selling, with an overall rating of Neutral and -22.64% Downside potential.

What Is STAAR Surgical's Earnings Per Share (TTM)?

The STAAR Surgical EPS (TTM) is -1.62.

When Is the Next STAAR Surgical Earnings Date?

STAAR Surgical will release its next earnings report on 06-05-2026.

From a Technical Analysis Perspective, Is STAA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

What Stock Exchange Does STAAR Surgical Trade On?

STAAR Surgical is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for STAAR Surgical?

The stock symbol for STAAR Surgical is "STAA."

How Many Times Has STAAR Surgical Stock Split?

STAAR Surgical has split 1 times.

How Many Employees Does STAAR Surgical Have?

STAAR Surgical has 921 employees.

What Is the STAA Premarket Price?

STAA's last pre-market stock price is 27.24. The pre-market share volume is 510.00, and the stock has changed by 0.05, or 0.18%.

What Is the STAA After Hours Price?

STAA's last after hours stock price is 27.02, the stock has changed by -0.27, or -0.99%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.